Summarized by Masters of Longevity from Frontiers - Health.
A CT‑clinical model predicted major pathological response after neoadjuvant tislelizumab, paclitaxel, and nedaplatin in 179 ESCC patients.
Key Takeaways
- Higher intermuscular fat was associated with greater likelihood of MPR.
- Absence of sarcopenia was associated with greater likelihood of MPR.
- Observational design has not established causal treatment effects.
